Skip to main content

Frequency Therapeutics, Inc. (FREQ)

NASDAQ: FREQ · IEX Real-Time Price · USD
5.52 0.48 (9.52%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap191.00M
Revenue (ttm)24.02M
Net Income (ttm)-73.42M
Shares Out34.60M
EPS (ttm)-2.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume352,892
Open5.30
Previous Close5.04
Day's Range5.02 - 5.73
52-Week Range4.87 - 58.37
Beta0.50
AnalystsBuy
Price Target13.25 (+140.0%)
Earnings DateNov 15, 2021

About FREQ

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of...

IndustryBiotechnology
IPO DateOct 3, 2019
Employees83
Stock ExchangeNASDAQ
Ticker SymbolFREQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FREQ stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 140.04% from the latest price.

Price Target
$13.25
(140.04% upside)
Analyst Consensus: Buy

News

Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

3 weeks ago - Zacks Investment Research

Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

3 weeks ago - Business Wire

Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs

In Frequency Therapeutics' short lifetime as a company, it's had its ups and downs. On Tuesday, during an R&D event day, the company unleashed a slew of announcements that add context to the development...

4 weeks ago - TechCrunch

Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorati...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

4 weeks ago - Business Wire

Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for

Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration an...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

1 month ago - Business Wire

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) St...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

1 month ago - Business Wire

Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors

Frequency Therapeutics Inc (NASDAQ: FREQ) has announced that four additional sensorineural hearing loss (SNHL) subjects from its FX-322-111 open-label study achieved statistically significant hearing im...

2 months ago - Benzinga

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improveme...

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerati...

2 months ago - Business Wire

Frequency Therapeutics to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...

3 months ago - Business Wire

Moore Kuehn, PLLC Encourages Investors of FREQ to Contact Law Firm

New York, New York--(Newsfile Corp. - August 12, 2021) -  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding po...

3 months ago - Newsfile Corp

Frequency Therapeutics, Inc. (FREQ) Reports Q2 Loss, Tops Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -1.96% and 26.49%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused ...

3 months ago - Business Wire

SHAREHOLDER ALERT: FREQ RKT QFIN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a lo...

Other symbols:QFINRKT
4 months ago - Accesswire

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FREQ, RKT and BZ

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participa...

Other symbols:BZRKT
4 months ago - Accesswire

FREQ Final Deadline Today: Rosen, National Trial Lawyers, Encourages Frequency Therapeutics, Inc. Investors to Secure...

New York, New York--(Newsfile Corp. - August 2, 2021) -  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) betwe...

4 months ago - Newsfile Corp

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Frequency Therapeutics, Inc. ...

Los Angeles, California--(Newsfile Corp. - August 2, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Frequency Therapeuti...

4 months ago - Newsfile Corp

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, RLX and DIDI

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Sh...

Other symbols:DIDIRLX
4 months ago - Accesswire

FREQ FINAL DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages Frequency Therapeutics, Inc. Investors to Secure Counsel Be...

New York, New York--(Newsfile Corp. - August 1, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) betwee...

4 months ago - Newsfile Corp

FREQ Final Deadline Monday: Rosen, Leading Trial Attorneys, Encourages Frequency Therapeutics, Inc. Investors with Lo...

New York, New York--(Newsfile Corp. - July 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Frequency Therapeutics, Inc. (NASDAQ: FREQ) between...

4 months ago - Newsfile Corp

FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeu...

New York, New York--(Newsfile Corp. - July 30, 2021) -  The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Frequency Therapeut...

4 months ago - Newsfile Corp

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FREQ, OCGN and BLCT

NEW YORK, NY / ACCESSWIRE / July 30, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Sha...

Other symbols:BLCTOCGN
4 months ago - Accesswire

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency ...

LOS ANGELES--(BUSINESS WIRE)---- $FREQ #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Frequency Therapeutics, Inc. (FREQ)

4 months ago - Business Wire

CLASS ACTION UPDATE for CCIV, FREQ and RLX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Sha...

NEW YORK, NY / ACCESSWIRE / July 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders i...

Other symbols:RLX
4 months ago - Accesswire

SHAREHOLDER ALERT: FREQ RLX DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / July 30, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a los...

Other symbols:DIDIRLX
4 months ago - Accesswire